Arcutis Biotherapeutics Inc (ARQT) concluded trading on Wednesday at a closing price of $13.70, with 4.6 million shares of worth about $62.98 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 58.02% during that period and on May 07, 2025 the price saw a loss of about -4.33%. Currently the company’s common shares owned by public are about 119.14M shares, out of which, 104.90M shares are available for trading.
Stock saw a price change of -8.12% in past 5 days and over the past one month there was a price change of -4.20%. Year-to-date (YTD), ARQT shares are showing a performance of -1.65% which increased to 71.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.99 but also hit the highest price of $17.75 during that period. The average intraday trading volume for Arcutis Biotherapeutics Inc shares is 2.52 million. The stock is currently trading -2.61% below its 20-day simple moving average (SMA20), while that difference is down -7.03% for SMA50 and it goes to 13.80% higher than SMA200.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) currently have 119.14M outstanding shares and institutions hold larger chunk of about 101.29% of that.
The stock has a current market capitalization of $1.71B and its 3Y-monthly beta is at 1.86. It has posted earnings per share of -$1.04 in the same period. It has Quick Ratio of 3.37 while making debt-to-equity ratio of 0.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARQT, volatility over the week remained 7.99% while standing at 7.79% over the month.
Stock’s fiscal year EPS is expected to rise by 50.37% while it is estimated to increase by 128.29% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 30, 2024 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by Jefferies stated Arcutis Biotherapeutics Inc (ARQT) stock as a Buy in their note to investors on August 28, 2024, suggesting a price target of $15 for the stock. On January 03, 2024, Mizuho Upgrade their recommendations, while on October 26, 2023, Mizuho Downgrade their ratings for the stock with a price target of $4. Stock get a Neutral rating from Goldman on October 13, 2023.
